An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Five Prime Therapeutics

Status

Conditions: Recurrent Bladder Cancer

Treatments: Drug: FPA144

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03801278

FPA144-006

Details and patient eligibility

About

This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer

Full description

This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab
2. Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration

Exclusion criteria

1. Pregnancy and lactation